- c. €3.4 million by issuing shares with warrants
- Subscription value: €1.37 for one share with warrants
- 1 warrant offers entitlement to 1 share to be issued at a value of €3
- Train interval: 3 years
- Visibility prolonged to finish 2025
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory Information:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible for PEA PME), a brand new era biotech firm devoted to the invention and growth of revolutionary therapies primarily based on the world’s solely pure recombinant apoA-I, proclaims the success of a capital enhance with cancellation of preferential subscription rights for the advantage of a class of individuals for an quantity of near €3.4 million by way of the problem of a most variety of 2,472,000 new shares, every with a warrant, at a subscription value of €1.37 per share with warrants.
Every new share shall be issued with a warrant, and every warrant will entitle its holder to subscribe for 1 new share to be issued at a value of €3.
Goal of the fundraising
The target of this fundraising is to strengthen the Firm’s money place as a part of its growth in sepsis and in the US, following the profitable pre-IND assembly with the FDA. The Firm’s monetary visibility has now been prolonged to finish 2025, with no additional drawdown of the equity-linked financing facility.
Phrases and circumstances of the problem
Additional to the selections taken by the selections by the Board of Administrators on June 19 and 21, the Chief Government Officer has immediately recorded full subscription of the next shares of two,472,000 extraordinary shares with a par worth of €0.05, every carrying a warrant to subscribe for brand new extraordinary shares. The shares with warrants issued at a value of €1.37, representing a nominal capital enhance of €123,600 and a problem premium of €3,263,040.
The subscription value of every share with warrant corresponds to the weighted common of the ten buying and selling days previous June 19, 2024, much less a ten% low cost and plus the estimated worth of the warrant of 0.18 euro.
Upon creation of the share with warrants, the warrants shall be indifferent from the shares.
This problem represents roughly 7.62% of the share capital as of the date of the problem choice.
The brand new shares carry dividend rights, are assimilated to present shares and carry the identical rights. They’re topic to all of the provisions of the Firm’s bylaws and are admitted to buying and selling on Euronext on the identical buying and selling line as the prevailing shares.
Every warrant will entitle its holder to subscribe for one new share at a value of €3.
The warrants are exercisable between November 30, 2024, and June 19, 2027. They’re transferable and negotiable however aren’t be topic of an software for admission to buying and selling on Euronext.
Train of all of the warrants may give rise to the problem of as much as 2,472,000 new extraordinary shares, representing extra gross proceeds of €7,416,000.
This operation entails a capital enhance with cancellation of preferential subscription rights for the advantage of a class of individuals, determined by the Board of Administrators on June 19 and 21, 2024, performing on the idea of the delegation granted by the 20th decision of the Firm’s Mixed Common Assembly of June 27, 2023.
Supply settlement
Settlement and supply is scheduled for Wednesday, July 3, 2024.
Problem proceeds
The gross proceeds from the shares with warrants problem quantity to €3,386,640, representing a internet quantity of €3,356,640, after deduction of issue-related prices.
Train of all of the warrants would generate extra gross proceeds of €7,416,000.
Shareholder construction
The variety of shares prone to be issued represents round 7.62% of the variety of shares excellent earlier than problem and seven.08% after problem of the shares with warrants.
By means of illustration, a shareholder who held a lot of shares representing 1% of ABIONYX’s share capital earlier than the deliberate problem would characterize 0.93% of the share capital after the shares with warrant problem (within the occasion of full subscription to the capital enhance) and 0.87% of the share capital (within the occasion of train of all of the warrants).
Shareholders earlier than and after capital enhance in % of capital
|
Shareholders |
12/31/2023 |
Put up-issuance of |
Put up train of warrants |
|||
|
Nb shares and |
% Capital and |
Nb shares and |
% Capital and |
Nb shares and |
% Capital and |
|
|
Voting rights |
Voting rights |
Voting rights |
Voting rights |
Voting rights |
Voting rights |
|
|
 |
 |
 |
 |
 |
 |
 |
|
Whole high administration |
6,148,342 |
18.94% |
6,148,342 |
17.60% |
6,148,342 |
16.44% |
|
Emmanuel Huynh |
4,348,882 |
13.40% |
4,348,882 |
12.45% |
4,348,882 |
11.63% |
|
Cyrille Tupin |
1,592,214 |
4.91% |
1,592,214 |
4.56% |
1,592,214 |
4.26% |
|
Christian Chavy |
207,246 |
0.64% |
207,246 |
0.59% |
207,246 |
0.55% |
|
Whole monetary shareholders |
6,622,787 |
20.40% |
9,094,787 |
26.04% |
11,566,787 |
30.92% |
|
Orsay 53 (represented by Mr. Jean-Gérard Galvez) |
 |
 |
2,331,000 |
6.67% |
4,662,000 |
12.46% |
|
Sadok Belmokhtar |
1,859,098 |
5.73% |
1,859,098 |
5.32% |
1,859,098 |
4.97% |
|
Luc Demarre |
1,846,457 |
5.69% |
1,987,457 |
5.69% |
2,128,457 |
5.69% |
|
BPI Participations (FR) |
1,630,451 |
5.02% |
1,630,451 |
4.67% |
1,630,451 |
4.36% |
|
Jean-Louis Dasseux |
1,286,781 |
3.96% |
1,286,781 |
3.68% |
1,286,781 |
3.44% |
|
Free float |
19,422,744 |
59.84% |
19,422,744 |
55.60% |
19,422,744 |
51.93% |
|
Treasury shares |
265,139 |
0.82% |
265,139 |
0.76% |
265,139 |
0.71% |
|
 |
 |
 |
 |
 |
 |
 |
|
TOTAL |
32,459,012 |
100.00% |
34,931,012 |
100.00% |
37,403,012 |
100.00% |
On the idea of data delivered to the Firm’s consideration, particularly for bearer shareholders through declarations of crossing thresholds (authorized and statutory).
Among the particular person shareholders listed within the desk above maintain all or a part of their pursuits by way of holding firms that they handle and management.
Absence of prospectus
In accordance with the provisions of Article 211-3 of the Common Laws of the Autorité des Marchés Financiers (AMF), the problem won’t give rise to a prospectus topic to AMF approval.
Threat components
Threat components are described within the Common Registration Doc 2023 (chapter 3) filed with the AMF beneath quantity D.24-0385 on April 30, 2024, and out there on the Firm’s web site: www.abionyx.com and that of the AMF: www.amf-france.org.
Variety of shares making up the share capital
Following the problem of shares with warrants, the share capital now stands at €1,746,550.60. It’s divided into 34,931,012 extraordinary shares with a par worth of €0.05, representing 34,931,012 theoretical voting rights.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech firm targeted on growing revolutionary medicines for ailments the place there isn’t any efficient or present therapy, even the rarest ones. The corporate expedites the event of novel therapeutics by way of an in depth experience in lipid science and a differentiated apoA-I-based know-how platform. ABIONYX Pharma is dedicated to radically enhancing therapy outcomes in Sepsis and important care.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240701444059/en/
NewCap
Investor relations
Nicolas Fossiez
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53
NewCap
Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15
Supply: ABIONYX Pharma
